ST Segment Elevation Myocardial Infarction, Elective Percutaneous Coronary Intervention
Conditions
Keywords
Prevention, Slow flow, No reflow, Nitroprusside, Tirofiban
Brief summary
Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during EPCI.
Interventions
Intracoronary infusion 50\ 100μg each time (repeated)
Intracoronary infusion 10μg/kg for single time
Intracoronary infusion 2ml for single time
Sponsors
Study design
Eligibility
Inclusion criteria
* Ischemic symptoms \< 2 weeks (\> 24 hours) * Continued ischemic chest pain \> 30min * ST-segment elevation ≥ 0.1 millivolt in 2 or more contiguous leads on the 12-lead ECG or new left bundle branch block (LBBB) * Detection of a rise of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL) * Elective coronary artery angiography was planned.
Exclusion criteria
* Emergency thrombolytic therapy was performed before elective coronary artery angiography * Cardiogenic shock with no response to hypervolemic treatment or vasopressor * Severe cardiomyopathy or valvular disease requiring intervention * Coronary ectasia * Severe heart failure * Contraindication or allergy to antiplatelet drugs * Contraindication or allergy to experimental drugs * Unable to receive at least 1 year of dual antiplatelet therapy * Active bleeding or extreme-risk for major bleeding * Severe liver or renal failure * Life expectancy \< 1 year * Unable or unwilling to provide informed consent * Women of child bearing potential * Under 18 years of age * Hemoglobin \< 90g/L * Platelet count \< 100×10\^9/L * Can not cooperate (with mental disorders or cognitive disorders)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow grade | 1 minute after stent implantation; 1 minute after balloon dilatation | grade 0, no myocardial blush or contrast density; grade 1, minimal myocardial blush or contrast density; grade 2, moderate myocardial blush or contrast density but less than that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery; grade 3, normal myocardial blush or contrast density comparable with that obtained during angiography of a contralateral or ipsilateral noninfarct-related coronary artery. |
| Coronary TIMI frame count | 1 minute after stent implantation; 1 minute after balloon dilatation | A continuous measurement assessing flow in the epicardial arteries. |
| Slow flow / no-reflow phenomenon | 1 minute after stent implantation; 1 minute after balloon dilatation | Slow flow phenomenon means delayed progression or lack of contrast medium through the coronary tree. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Main adverse cardiovascular and cerebrovascular events (MACCE) | at 1 day post-PCI, at follow up of 1, 3, 6,12 months post-PCI | Death, Cardiac death, Rehospitalization (Heart failure) , Non-fatal myocardial infarction, Target vessel myocardial infarction, Target lesion revascularization, Target vessel revascularization, Ischemic-driven revascularization, Stent thrombosis, Bleeding, Cerebrovascular events, etc. |
Countries
China